A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Brexpiprazole in Treatment of Children and Adolescents With Irritability
Project Description:
To evaluate the efficacy, safety, and tolerability of
brexpiprazole in reducing irritability in children and
adolescents ages 5 to 17 years with a diagnosis of ASD.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Children/Adolescents with Disabilities/SHCN
Unserved or Under-served Populations:
None
Primary Target Audience Geographic Descriptor:
State
COVID-19 Related Data:
N/A